CD274 and non-small cell lung carcinoma: For example, an experiment involving patients with advanced NSCLC treated with PD‐1/PD‐L1 inhibitors revealed that the presence of exosomal hsa‐miR‐320d, hsa‐miR‐320c, and hsa‐miR‐320b could serve as potential indicators of improved efficacy in PD‐1/PD‐L1 immunotherapy.161